UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 210

Sortiert nach

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis

The lancet oncology, 2016-06, Vol.17 (6), p.801-810

2016

Volltextzugriff (PDF)

Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial

Journal of clinical oncology, 2011-05, Vol.29 (13), p.1715-1721

2011

Volltextzugriff (PDF)

Metastatic Pancreatic Cancer: ASCO Guideline Update

Journal of clinical oncology, 2020-09, Vol.38 (27), p.3217-3230

2020

Volltextzugriff (PDF)

Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial

Journal of clinical oncology, 2013-01, Vol.31 (1), p.23-29

2013

Volltextzugriff (PDF)

Current standards and new innovative approaches for treatment of pancreatic cancer

European journal of cancer (1990), 2016-04, Vol.57, p.10-22

2016

Volltextzugriff (PDF)

An update on treatment options for pancreatic adenocarcinoma

Therapeutic Advances in Medical Oncology, 2019, Vol.11, p.1758835919875568-1758835919875568

2019

Volltextzugriff (PDF)

Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer

Cancers, 2021-09, Vol.13 (18), p.4724

2021

Volltextzugriff (PDF)

Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer

Journal of clinical oncology, 2012-12, Vol.30 (36), p.4558-4565

2012

Volltextzugriff (PDF)

Chemoradiation Followed by Surgery Compared With Chemoradiation Alone in Squamous Cancer of the Esophagus: FFCD 9102

Journal of clinical oncology, 2007-04, Vol.25 (10), p.1160-1168

2007

Volltextzugriff (PDF)

Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2

Journal of clinical oncology, 2010-04, Vol.28 (10), p.1638-1644

2010

Volltextzugriff (PDF)

When a joint model should be preferred over a linear mixed model for analysis of longitudinal health-related quality of life data in cancer clinical trials

BMC medical research methodology, 2023-02, Vol.23 (1), p.36-36, Article 36

2023

Volltextzugriff (PDF)

Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions

Therapeutic Advances in Gastroenterology, 2017-08, Vol.10 (8), p.631-645

2017

Volltextzugriff (PDF)

Induction Chemotherapy and Dose Intensification of the Radiation Boost in Locally Advanced Anal Canal Carcinoma: Final Analysis of the Randomized UNICANCER ACCORD 03 Trial

Journal of clinical oncology, 2012-06, Vol.30 (16), p.1941-1948

2012

Volltextzugriff (PDF)

Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203

Journal of clinical oncology, 2006-10, Vol.24 (28), p.4620-4625

2006

Volltextzugriff (PDF)

Did the COVID-19 pandemic delay treatment for localized breast cancer patients? A multicenter study

PloS one, 2024-05, Vol.19 (5), p.e0304556

2024

Volltextzugriff (PDF)

Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial

PloS one, 2017-09, Vol.12 (9), p.e0183288

2017

Volltextzugriff (PDF)

Capecitabine plus oxaliplatin (XELOX) versus 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) as first‐line treatment for metastatic colorectal cancer

International journal of cancer, 2011-02, Vol.128 (3), p.682-690

2011

Volltextzugriff (PDF)

Acceptability and usefulness of the EORTC 'Write In three Symptoms/Problems' (WISP): a brief open-ended instrument for symptom assessment in cancer patients

Health and quality of life outcomes, 2024-03, Vol.22 (1), p.28-28, Article 28

2024

Volltextzugriff (PDF)

Comment on “Locoregional Failure During and After Short-Course Radiotherapy Followed by Chemotherapy and Surgery Compared to Long-Course Chemoradiotherapy and Surgery: A Five-Year Follow-Up of the RAPIDO Trial”: The RAPIDO Trial Does Not Achieve Its Primary Endpoint

Annals of surgery open, 2023-06, Vol.4 (2), p.e288-e288

2023

Volltextzugriff (PDF)

The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer

Current oncology reports, 2013-04, Vol.15 (2), p.182-189

2013

Volltextzugriff (PDF)

Item response models for the longitudinal analysis of health-related quality of life in cancer clinical trials

BMC medical research methodology, 2017-09, Vol.17 (1), p.148-148, Article 148

2017

Volltextzugriff (PDF)

Preneoplastic Lesions in Surgical Specimens Do Not Worsen the Prognosis of Patients Who Underwent Surgery for Pancreatic Adenocarcinoma: Post-Hoc Analysis of the PRODIGE 24-CCTG PA 6 Trial

Cancers, 2022-08, Vol.14 (16), p.3945

2022

Volltextzugriff (PDF)

XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer

Journal of clinical oncology, 2004-06, Vol.22 (11), p.2084-2091

2004

Volltextzugriff (PDF)

COVID-19 Infection despite Previous Vaccination in Cancer Patients and Healthcare Workers: Results from a French Prospective Multicenter Cohort (PAPESCO-19)

Cancers, 2023-09, Vol.15 (19), p.4777

2023

Volltextzugriff (PDF)

1 – 25 von 210

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(196)
Mit Volltextzugriff
(192)

Publikationsform

Artikel
(209)
Reviews
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(146)
Life Sciences & Biomedicine
(143)
Humans
(119)
Oncology
(106)
Female
(71)
Male
(63)
Middle Aged
(61)
Aged
(60)
Life Sciences
(55)
Quality Of Life
(55)
Adult
(52)
Cancer
(51)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(45)
Tumors
(36)
Chemotherapy
(32)
Biological And Medical Sciences
(31)
Medical Sciences
(31)
Pancreatic Cancer
(27)
Santé Publique Et Épidémiologie
(27)
Aged, 80 And Over
(26)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis

Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial

Metastatic Pancreatic Cancer: ASCO Guideline Update

Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial

Current standards and new innovative approaches for treatment of pancreatic cancer

An update on treatment options for pancreatic adenocarcinoma

Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer

Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial

Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer

Chemoradiation Followed by Surgery Compared With Chemoradiation Alone in Squamous Cancer of the Esophagus: FFCD 9102

Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2

When a joint model should be preferred over a linear mixed model for analysis of longitudinal health-related quality of life data in cancer clinical trials

Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions

Induction Chemotherapy and Dose Intensification of the Radiation Boost in Locally Advanced Anal Canal Carcinoma: Final Analysis of the Randomized UNICANCER ACCORD 03 Trial

Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203

Did the COVID-19 pandemic delay treatment for localized breast cancer patients? A multicenter study

Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial

Capecitabine plus oxaliplatin (XELOX) versus 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) as first‐line treatment for metastatic colorectal cancer

Acceptability and usefulness of the EORTC 'Write In three Symptoms/Problems' (WISP): a brief open-ended instrument for symptom assessment in cancer patients

Comment on “Locoregional Failure During and After Short-Course Radiotherapy Followed by Chemotherapy and Surgery Compared to Long-Course Chemoradiotherapy and Surgery: A Five-Year Follow-Up of the RAPIDO Trial”: The RAPIDO Trial Does Not Achieve Its Primary Endpoint

The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer

Item response models for the longitudinal analysis of health-related quality of life in cancer clinical trials

Preneoplastic Lesions in Surgical Specimens Do Not Worsen the Prognosis of Patients Who Underwent Surgery for Pancreatic Adenocarcinoma: Post-Hoc Analysis of the PRODIGE 24-CCTG PA 6 Trial

XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer

COVID-19 Infection despite Previous Vaccination in Cancer Patients and Healthcare Workers: Results from a French Prospective Multicenter Cohort (PAPESCO-19)

Suchergebnisse filtern